Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: Results from the DYNAGITO study

22Citations
Citations of this article
56Readers
Mendeley users who have this article in their library.

Abstract

Background: The DYNAGITO study was a Phase IIIb, randomized, double-blind, multicenter, active-controlled, parallel-group, 52-week study designed to determine the efficacy and safety of tiotropium and olodaterol combination therapy (TIO+OLO 5/5 μg) versus tiotropium monotherapy (TIO 5 μg) for reducing moderate-to-severe exacerbations of COPD. This is a prespecified analysis of the DYNAGITO data in Japanese patients. Patients and methods: Enrolled patients had a diagnosis of COPD with at least one moderate-to-severe exacerbation in the previous 12 months. Of the total 7,880 treated patients in the DYNAGITO study, 461 (TIO+OLO 5/5 μg: n=226, TIO 5 μg: n=235) were Japanese. The primary endpoint was the annualized rate of moderate-to-severe COPD exacerbations. The key secondary endpoint was the time to first moderate-to-severe COPD exacerbation, and other secondary endpoints included the annualized rate of exacerbations leading to hospitalization, time to first COPD exacerbation leading to hospitalization, and all-cause mortality. Safety data were analyzed descriptively. Results: Combination therapy with TIO+OLO resulted in a 29% lower rate of moderate-to-severe COPD exacerbations relative to TIO monotherapy (rate ratio 0.71; 99% CI: 0.46, 1.10; p=0.0434). The risk of a first moderate-to-severe COPD exacerbation was 19% lower with TIO+OLO combination therapy than with TIO monotherapy (HR 0.81; 99% CI: 0.57, 1.17; p=0.1379), although this difference was not statistically significant. The annualized rate of COPD exacerbations requiring hospitalization was 14% lower in the TIO+OLO arm than in the TIO arm (rate ratio 0.86; 95% CI: 0.52, 1.42; p=0.5654). The adverse event incidence was balanced between treatment arms. Conclusion: In a prespecified subgroup analysis of Japanese patients in the DYNAGITO study, combination therapy with TIO+OLO was more effective than TIO in reducing exacerbations. Both treatments were well tolerated.

References Powered by Scopus

Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report

2484Citations
N/AReaders
Get full text

Risk of cancer from diagnostic X-rays: Estimates for the UK and 14 other countries

1418Citations
N/AReaders
Get full text

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide

771Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Tiotropium/Olodaterol: A Review in COPD

22Citations
N/AReaders
Get full text

The IMPACT study – single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: Efficacy and safety in a Japanese population

21Citations
N/AReaders
Get full text

Long-term safety and efficacy of budesonide/ glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology in Japanese patients with COPD

16Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Ichinose, M., Nishimura, M., Akimoto, M., Kurotori, Y., Zhao, Y., de la Hoz, A., & Mishima, M. (2018). Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: Results from the DYNAGITO study. International Journal of COPD, 13, 2271–2278. https://doi.org/10.2147/COPD.S169941

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 14

70%

Researcher 4

20%

Professor / Associate Prof. 1

5%

Lecturer / Post doc 1

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 17

57%

Pharmacology, Toxicology and Pharmaceut... 6

20%

Nursing and Health Professions 5

17%

Agricultural and Biological Sciences 2

7%

Save time finding and organizing research with Mendeley

Sign up for free